Cabaletta Bio, Inc. terminated a $200 million Sales Agreement with TD Cowen on June 11, 2025, after having sold shares worth approximately $7.9 million, leaving about $192 million unsold. On the same day, they released promising updates from their clinical trials, showing significant clinical responses from 18 patients in ongoing studies.